Cartilage Repair Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sports-related cartilage repair addresses focal chondral and osteochondral defects arising from acute traumatic events or repetitive mechanical loading in athletes. Articular cartilage—the smooth hyaline tissue covering the ends of bones—has minimal intrinsic healing capacity due to its avascular nature, making surgical intervention necessary for significant defects that cause pain, swelling, and functional limitations.

The treatment hierarchy begins with bone marrow stimulation. Microfracture is the most widely performed first-line surgical option: multiple perforations are made through the subchondral bone plate using an arthroscopic awl, allowing marrow-derived mesenchymal stem cells to migrate into the defect and form fibrocartilage repair tissue. Fibrocartilage is mechanically inferior to native hyaline cartilage (lower collagen II content, greater type I collagen), limiting its durability under athletic loading, particularly in defects larger than 2–3 cm².

OATS (osteochondral autograft transfer system) harvests one or more cylindrical plugs of bone and cartilage from a low-weight-bearing area of the joint (typically the peripheral femoral condyles) and press-fits them into the defect. This transfers genuine hyaline cartilage and provides stable bony fixation, making it optimal for small defects under 2 cm².

MACI (matrix-associated autologous chondrocyte implantation) is the most biologically advanced technique. In a first-stage procedure, a cartilage biopsy is taken arthroscopically. Chondrocytes are expanded in cell culture over 4–6 weeks, then seeded onto a collagen scaffold membrane. In the second-stage open or arthroscopic procedure, the MACI membrane is trimmed to fit and sutured or glued into the prepared defect. MACI produces hyaline-like repair tissue confirmed by MRI T2 mapping and is best suited for defects 3–10 cm².

Sports-related cartilage repair is indicated for focal chondral and osteochondral defects in young to middle-aged athletes who remain symptomatic despite conservative management. The lesions must be focal—circumscribed defects with healthy surrounding cartilage—rather than diffuse articular cartilage loss (osteoarthritis), for which these techniques are inappropriate.

Traumatic chondral lesions from sports injuries are the primary indication: these include shear injuries from pivoting or contact impacts in soccer, basketball, rugby, and skiing, and direct blows to the patellofemoral joint. Osteochondritis dissecans (OCD) in young athletes—a condition where a fragment of cartilage and underlying bone separates from the joint surface—is a key indication, particularly in the knee and ankle.

Post-meniscectomy cartilage defects occur when the cartilage-protecting function of the meniscus is compromised; repair of these defects is most effective when combined with meniscal allograft transplantation. Patellar chondral injury following acute dislocation (shear fracture of the patella or lateral femoral condyle) frequently requires cartilage repair. In the ankle, talar dome osteochondral lesions (OLT) from repeated sprains or acute trauma cause persistent pain in athletes; grades I–III are treated arthroscopically while larger lesions require OATS or MACI. Glenohumeral chondral defects from recurrent shoulder dislocation, though less common, may also require cartilage restoration as part of a comprehensive surgical plan.

Optimal candidates for cartilage repair are young to middle-aged athletes (generally under 50) with focal Outerbridge grade III–IV cartilage defects identified on MRI or diagnostic arthroscopy. Defect size measured at arthroscopy determines technique selection: microfracture for defects under 4 cm², OATS for defects 1–4 cm² with an accessible donor site, and MACI for defects 3–10 cm² or where microfracture has previously failed.

Several mechanical prerequisites must be met for any cartilage repair to succeed. Limb alignment must be corrected: varus malalignment concentrates load on the medial compartment and will cause repair failure—high tibial osteotomy (HTO) should precede or be performed simultaneously with cartilage repair in patients with varus deformity. Ligamentous instability must be addressed: cartilage repairs in ACL-deficient knees fail at high rates without concurrent reconstruction. The surrounding cartilage must be mechanically stable and not globally degenerative.

Pre-operative workup includes weight-bearing X-rays (assess alignment and joint space), MRI with dedicated cartilage sequences (3T preferred, T2 mapping, dGEMRIC), and often diagnostic arthroscopy to precisely size and characterize the defect. BMI under 35 is preferred, as obesity significantly impairs outcomes. Smoking cessation is strongly recommended. For MACI, the cartilage biopsy and cell expansion phase adds 4–6 weeks to the planning timeline before implantation surgery.

Articular cartilage repair options span from simple marrow stimulation to complex biological and structural reconstruction:

• Microfracture: Arthroscopic awls create perforations (3 mm deep, 3–4 mm apart) through subchondral bone, releasing marrow elements including mesenchymal stem cells into the cartilage defect. A fibrocartilage clot forms and matures over 6–12 months. Best results for small defects (<2 cm²) in young active patients (<40 years). Revision rates of 20–30% at 5 years as fibrocartilage (type I collagen) lacks the biomechanical properties of native hyaline cartilage (type II collagen).
• Autologous chondrocyte implantation (ACI/MACI): A two-stage procedure. Stage 1: Arthroscopic biopsy harvests 200–300 mg of chondrocytes from a non-load-bearing area. Cells are cultured and expanded over 4–6 weeks in a GMP laboratory. Stage 2 (open or arthroscopic): Expanded chondrocytes (ACI) or cells seeded onto a collagen membrane scaffold (MACI — matrix-induced ACI) are implanted into the prepared defect. MACI produces true hyaline-like cartilage regeneration — type II collagen — and achieves superior long-term outcomes compared to microfracture for large defects (>2–3 cm²) at 3–5 years (SUMMIT trial). FDA-approved (Vericel) and EMA-approved in Europe.
• Osteochondral autograft transplantation (OATS/mosaicplasty): One or multiple cylindrical osteochondral plugs (6–10 mm diameter) harvested from low-load-bearing areas of the same knee (notch, lateral trochlea periphery) are press-fit into the defect. Single-plug OATS (OAT) for focal lesions <2 cm²; mosaicplasty with multiple smaller plugs for larger defects. Immediate structural restoration of hyaline cartilage and subchondral bone. Limited by donor site availability and morbidity.
• Osteochondral allograft transplantation (OCA): Fresh or fresh-frozen donor osteochondral grafts match the patient's defect size (up to 10 cm²). No donor site morbidity; appropriate for large or complex defects, failed prior cartilage procedures, or subchondral bone involvement. Fresh allografts (used within 28 days) contain viable chondrocytes for optimal integration. Disease transmission risk is negligible with modern tissue banking protocols.
• Particulated juvenile cartilage (DeNovo NT): Minced juvenile allograft cartilage particles mixed with fibrin glue achieve cartilage regeneration through juvenile chondrocyte migration and matrix production. FDA-cleared for single-step arthroscopic implantation without cell culture. Good short-term evidence; long-term data maturing.

Outcomes from cartilage repair depend substantially on technique, defect characteristics, and patient adherence to the demanding post-operative rehabilitation protocol. The SUMMIT trial—the pivotal MACI versus microfracture RCT—demonstrated statistically and clinically significant superiority of MACI at 5 years, with 87% treatment success versus 68% for microfracture, using KOOS pain and function as primary endpoints.

Microfracture produces good outcomes in the short term (70–80% improvement in IKDC and KOOS scores at 2 years) for small defects in younger patients. However, results deteriorate progressively beyond 3–5 years for larger defects, as fibrocartilage undergoes mechanical degeneration under sporting loads. MRI T2 mapping at 12–24 months reliably identifies poor repair tissue fill and may predict those requiring secondary procedures.

OATS achieves 80–90% good-to-excellent outcomes at 5 years for small defects (under 2 cm²), with the advantage of transplanting genuine hyaline cartilage. Graft integration and congruence are critical: well-placed plugs that are flush with the articular surface perform significantly better than proud or recessed grafts.

Return to sport rates vary by technique: microfracture achieves 60–70% return (with higher failure rates by 5 years in demanding athletes); OATS and MACI achieve 75–85% return at 12–18 months. MRI T2 mapping at 12–24 months post-MACI confirms hyaline-like repair tissue in 75–85% of cases, supporting long-term durability. Patient-reported outcomes (KOOS, IKDC, Lysholm) improve substantially from baseline across all techniques in appropriately selected patients.

Each cartilage repair technique carries technique-specific risks alongside general surgical risks. Rehabilitation non-compliance is the single most important predictor of failure across all techniques—premature loading destroys the repair tissue before it has matured.

Microfracture risks include formation of inferior fibrocartilage that fails mechanically under sporting loads by 5 years in larger defects or high-demand athletes; subchondral cyst formation from the perforation sites (10–15%), which can cause persistent pain; and incomplete defect fill (25–40%). Repeat microfracture shows significantly diminished outcomes compared to primary procedures.

OATS-specific risks include donor-site morbidity at the harvest site: pain, articular surface irregularity, and chondral degeneration are reported in 15–20% of patients. Graft subsidence into the recipient site occurs if the press-fit is inadequate. Surface congruence mismatch—particularly on curved surfaces such as the femoral condyle where a flat cylindrical plug cannot perfectly match—causes edge loading and potential fibrocartilage rim deterioration.

MACI risks include incomplete graft integration (5–10%), graft delamination (separation of the scaffold from the bone), periosteal hypertrophy (historical issue with periosteal-covered techniques, less common with collagen membrane), and the inherent risk of the first-stage biopsy procedure (small but non-zero infection and cartilage damage risk). MACI is substantially more expensive than microfracture and requires high patient commitment to a 12–18 month rehabilitation timeline. All techniques carry standard surgical risks: infection (<1%), DVT, and anesthesia complications.

Cartilage repair rehabilitation requires extended protected recovery to allow tissue maturation:

• Microfracture (weeks 0–6): Non-weight-bearing or protected weight-bearing for 6 weeks to allow fibrocartilage clot formation without mechanical disruption. CPM (continuous passive motion) machine use for 6–8 hours/day accelerates cartilage formation and prevents adhesions. Aquatic physiotherapy at 4 weeks for range of motion and low-impact strengthening.
• MACI rehabilitation: Similar initial non-weight-bearing period (4–6 weeks for femoral condyle lesions). Gentle range of motion initiated day 1. Progressive weight-bearing at 6–8 weeks. Running at 12–16 months; return to sport at 18 months minimum. MRI at 12 months confirms graft fill and integration quality.
• OATS/OCA recovery: Weight-bearing progression over 6–8 weeks. Running at 4–6 months; return to sport at 9–12 months for OATS, 12–18 months for OCA.
• Imaging follow-up: MRI (with cartilage-sensitive sequences — T2 mapping, dGEMRIC) at 6, 12, and 24 months post-procedure assesses graft fill, signal intensity, and integration. Biopsy (rarely performed) confirms histological cartilage quality.
• Long-term outcomes: MACI and OCA achieve durable outcomes in 70–80% of patients at 5 years for large defects. Return to preinjury level sport is achieved in 50–70% of recreational athletes. Factors predicting better outcomes: younger age, smaller defect, shorter symptom duration, and absence of malalignment (which must be corrected concurrently).

Cartilage repair costs vary significantly by technique. Microfracture is the least expensive (arthroscopic only); OATS adds graft harvesting complexity; MACI adds the two-stage procedure, cell culture laboratory costs, and the biological implant. Costs listed are inclusive of surgery, anesthesia, and hospital stay but not rehabilitation.

Microfracture: India: $2,000–$5,000 | USA: $8,000–$20,000 | UK (Private): £5,000–£12,000 | Australia: $6,000–$15,000

OATS (Osteochondral Autograft Transfer): India: $3,000–$7,000 | Thailand: $6,000–$14,000 | Turkey: $4,000–$9,000 | USA: $12,000–$30,000

MACI (Matrix-Associated Autologous Chondrocyte Implantation): India: $6,000–$15,000 | Germany: €15,000–€35,000 (country of origin for ACI technique) | Australia: $18,000–$40,000 | USA: $25,000–$60,000 (the ACI biological product alone costs $15,000–$25,000)

Medical tourism significantly reduces costs for microfracture and OATS, with India and Thailand offering well-equipped arthroscopic centers. MACI requires the biological product availability and specialized cell culture facilities—availability varies by country. Long-term perspective: investing in a superior technique (MACI vs microfracture) may reduce the need for repeat procedures and ultimately joint replacement, representing better long-term value for young, athletic patients.

Non-surgical and injection-based options are appropriate for degenerative cartilage loss or when patient factors preclude surgery:

• Intra-articular PRP (platelet-rich plasma): Three weekly injections of autologous concentrated growth factors reduce pain and improve function in knee osteoarthritis and symptomatic chondromalacia. Level I evidence from multiple RCTs demonstrates superiority over hyaluronic acid and saline injection for knee OA pain at 6–12 months. Not a regenerative treatment for full-thickness defects but an effective non-surgical adjunct.
• Hyaluronic acid viscosupplementation: 3–5 weekly intra-articular injections provide lubrication and modest anti-inflammatory benefit in early osteoarthritis. Effect size is smaller than PRP in comparative trials but larger than placebo; suitable for older patients with degenerative rather than traumatic chondral pathology.
• Unloader bracing: For unicompartmental knee OA with malalignment — valgus unloader bracing redistributes load away from the diseased compartment, reducing pain and improving function without surgery. Appropriate as temporizing measure or when surgery is not appropriate.
• Partial or total knee replacement: For extensive articular cartilage loss across multiple compartments in older patients, joint replacement provides reliable pain relief and functional restoration when biological repair is not feasible. Unicompartmental knee replacement for isolated medial compartment disease is minimally invasive with rapid recovery.